Focused On-demand Library for Eukaryotic translation initiation factor 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P41567

UPID:

EIF1_HUMAN

Alternative names:

A121; Protein translation factor SUI1 homolog; Sui1iso1

Alternative UPACC:

P41567; Q9UNQ9

Background:

Eukaryotic translation initiation factor 1 (EIF1), known alternatively as A121, Protein translation factor SUI1 homolog, or Sui1iso1, plays a pivotal role in the initiation phase of protein synthesis. It is a key component of the 43S pre-initiation complex, facilitating mRNA scanning, start codon recognition, and ensuring the fidelity of initiation codon selection through its interaction with other initiation factors and the ribosomal subunit. EIF1's ability to regulate the mRNA binding channel's dynamics is crucial for mRNA recruitment and scanning processes.

Therapeutic significance:

Understanding the role of Eukaryotic translation initiation factor 1 could open doors to potential therapeutic strategies.